Medical Therapy for Acute Decompensated Heart Failure: What Recent Clinical Trials Have Taught Us About Diuretics and Vasodilators

Overview

Journal Curr Heart Fail Rep

Publisher Current Science

Date 2011 Aug 30

PMID 21874282

Authors

Catherine Marti

Robert Cole

Andreas Kalogeropoulos

Vasiliki Georgiopoulou

Javed Butler

Affiliations

Soon will be listed here.

Abstract

Diuretics and vasodilators have been the cornerstone of heart failure (HF) therapy for decades. Although not shown to reduce mortality, diuretic and vasodilator therapy remain commonplace for treating acute decompensated HF, with diuretics being the mainstay of therapy for the removal of excess fluid in all patients with HF. This article discusses results of recent trials concerning diuretic or vasodilator therapy and HF, including the Diuretic Optimization Strategies Evaluation (DOSE) trial, the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT), and the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST), as well as results from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial and the Preliminary Study of Relaxin in Acute Heart Failure (Pre-RELAX-AHF).

References

Li Z, TenHoor C, Marbury T, Swan S, Ticho B, Rogge M . Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. J Clin Pharmacol. 2010; 51(7):1004-14. DOI: 10.1177/0091270010377633. View

Massie B, OConnor C, Metra M, Ponikowski P, Teerlink J, Cotter G . Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010; 363(15):1419-28. DOI: 10.1056/NEJMoa0912613. View

Sackner-Bernstein J, Kowalski M, Fox M, Aaronson K . Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005; 293(15):1900-5. DOI: 10.1001/jama.293.15.1900. View

Salvador D, Rey N, Ramos G, Punzalan F . Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004; (1):CD003178. DOI: 10.1002/14651858.CD003178.pub2. View

Mentzer Jr R, Oz M, Sladen R, Graeve A, Hebeler Jr R, Luber Jr J . Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial. J Am Coll Cardiol. 2007; 49(6):716-26. DOI: 10.1016/j.jacc.2006.10.048. View

Pelleg A, Porter R . The pharmacology of adenosine. Pharmacotherapy. 1990; 10(3):157-74. View

Hunt S, Abraham W, Chin M, Feldman A, Francis G, Ganiats T . ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001.... Circulation. 2005; 112(12):e154-235. DOI: 10.1161/CIRCULATIONAHA.105.167586. View

Gheorghiade M, Gattis W, OConnor C, Adams Jr K, Elkayam U, Barbagelata A . Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004; 291(16):1963-71. DOI: 10.1001/jama.291.16.1963. View

Cohn J . Blood pressure and cardiac performance. Am J Med. 1973; 55(3):351-61. DOI: 10.1016/0002-9343(73)90135-6. View

10.

Gottlieb S . Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs. 2001; 61(10):1387-93. DOI: 10.2165/00003495-200161100-00002. View

11.

Cohn J, Franciosa J . Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977; 297(1):27-31. DOI: 10.1056/NEJM197707072970105. View

12.

Abraham W, Adams K, Fonarow G, Costanzo M, Berkowitz R, Lejemtel T . In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005; 46(1):57-64. DOI: 10.1016/j.jacc.2005.03.051. View

13.

Gottlieb S, Ticho B, Deykin A, Abraham W, DeNofrio D, Russell S . Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure. J Clin Pharmacol. 2010; 51(6):899-907. DOI: 10.1177/0091270010375957. View

14.

Levy D, Kenchaiah S, Larson M, Benjamin E, Kupka M, Ho K . Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347(18):1397-402. DOI: 10.1056/NEJMoa020265. View

15.

Munger K, Jackson E . Effects of selective A1 receptor blockade on glomerular hemodynamics: involvement of renin-angiotensin system. Am J Physiol. 1994; 267(5 Pt 2):F783-90. DOI: 10.1152/ajprenal.1994.267.5.F783. View

16.

Katz A . The myocardium in congestive heart failure. Am J Cardiol. 1989; 63(2):12A-16A. DOI: 10.1016/0002-9149(89)90386-x. View

17.

Ponikowski P, Mitrovic V, OConnor C, Dittrich H, Cotter G, Massie B . Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. Eur J Heart Fail. 2010; 12(11):1238-46. DOI: 10.1093/eurjhf/hfq137. View

18.

SONNENBLICK E, Downing S . Afterload as a primary determinat of ventricular performance. Am J Physiol. 1963; 204:604-10. DOI: 10.1152/ajplegacy.1963.204.4.604. View

19.

Franciosa J, Limas C, Guiha N, Rodriguera E, Cohn J . Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet. 1972; 1(7752):650-4. DOI: 10.1016/s0140-6736(72)90460-6. View

20.

Gheorghiade M, Konstam M, Burnett Jr J, Grinfeld L, Maggioni A, Swedberg K . Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297(12):1332-43. DOI: 10.1001/jama.297.12.1332. View